NewAmsterdam Pharma Co N.V (NAMS) Equity Ratio: 2022-2025
Historic Equity Ratio for NewAmsterdam Pharma Co N.V (NAMS) over the last 2 years, with Sep 2025 value amounting to 0.93.
- NewAmsterdam Pharma Co N.V's Equity Ratio rose 7.32% to 0.93 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.93, marking a year-over-year increase of 7.32%. This contributed to the annual value of 0.88 for FY2024, which is 5.44% up from last year.
- Latest data reveals that NewAmsterdam Pharma Co N.V reported Equity Ratio of 0.93 as of Q3 2025, which was down 3.07% from 0.96 recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma Co N.V's Equity Ratio registered a high of 0.96 during Q2 2025, and its lowest value of 0.83 during Q4 2023.
- Over the past 3 years, NewAmsterdam Pharma Co N.V's median Equity Ratio value was 0.88 (recorded in 2024), while the average stood at 0.89.
- As far as peak fluctuations go, NewAmsterdam Pharma Co N.V's Equity Ratio decreased by 7.56% in 2023, and later grew by 12.67% in 2025.
- Quarterly analysis of 4 years shows NewAmsterdam Pharma Co N.V's Equity Ratio stood at 0.90 in 2022, then declined by 7.56% to 0.83 in 2023, then increased by 5.44% to 0.88 in 2024, then increased by 7.32% to 0.93 in 2025.
- Its Equity Ratio was 0.93 in Q3 2025, compared to 0.96 in Q2 2025 and 0.95 in Q1 2025.